Home > Boards > US OTC > Biotechs >

Endonovo Therapeutics Inc. (ENDV)

Add ENDV Price Alert      Hide Sticky   Hide Intro
Moderator: brojazzy, Craig305
Search This Board: 
Last Post: 12/3/2020 8:33:36 PM - Followers: 193 - Board type: Free - Posts Today: 0


Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit



Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders

LOS ANGELES, CA, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it has acquired the PEMF assets of Rio Grande Neurosciences, Inc. (“RGN”) for $4.5 million and settled its lawsuit concerning RGN’s termination of the binding letter agreement to acquire RGN dated July 8, 2016.

Under the terms of the settlement agreement, RGN paid $150,000 to Endonovo Therapeutics and granted an exclusive option to Endonovo to acquire the PEMF assets of RGN for $4.5 million, which the Company exercised per the settlement agreement. The settlement has resulted in the dismissal of the case in the Superior Court of California, County of Los Angeles.

Endonovo believes settling the case at this time is in the best interest of all parties, and its acquisition of RGN's PEMF assets could result in substantial benefit to its shareholders. 

The PEMF assets includes a portfolio of intellectual property, including 27 issued patents with foreign patent protection covering the therapeutic use of PEMF for the treatment of various central nervous system disorders. Endonovo Therapeutics will initiate and fund both currently planned and all future clinical trials to evaluate the use of PEMF in the treatment of central nervous system disorders, including traumatic brain injury, post-concussion syndrome, stroke and multiple sclerosis.

The PEMF assets additionally include a portable, disposable PEMF device with a CE Mark and an FDA 510(k) clearance for the treatment of soft tissue injuries and post-surgical pain and edema in addition to medical reimbursement for the treatment of chronic wounds. Endonovo Therapeutics will begin the commercialization of the PEMF assets through licensing and joint venture agreements and the creation of various sales channels and distribution agreements.

The Company has posted an overview of the PEMF assets in the presentations page on its investor relations website.

About Traumatic Brain Injury:

Traumatic Brain Injury (TBI), also called craniocerebral trauma is a brain dysfunction caused by an outside force, usually a violent blow to the head. In 2010, approximately 2.5 million people sustained a traumatic brain injury. More than half of all brain injuries are bad enough to require people to go to the hospital. A severe TBI not only affects the quality of life of an individual and their family, but also imposes a large economic toll on society. The economic cost of TBI in 2010 was estimated to be approximately $76.5 billion. Severe brain injuries can lead to permanent brain damage or death. Half of all TBIs are from motor vehicle accidents, with military personnel in combat zones and athletes also being at risk.

About Chronic Wounds:

A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do. Wounds that do not heal within three months are often considered chronic. Some of the most common types of chronic wounds include, ischemic wounds, radiation poisoning wounds, surgical wounds and ulcers, such as arterial ulcers, venous ulcers, diabetic ulcers and pressure ulcers. The increasing prevalence of diabetes mellitus is a driving factor in the occurrence of chronic wounds, such as diabetic ulcers. A recent study published in Value in Health, found that approximately 15% of Medicare beneficiaries in 2014 (8.2 million) had at least one type of wound or infection at an estimated cost of nearly $32 billion to CMS. As the US Centers for Medicare and Medicaid Services (CMS) moves toward an outcome-based model, CMS needs to take a careful look at wound care, according to the authors of the study. New, more effective and equally important, more cost effective therapies are needed as the cost associated with treating these chronic wounds continues to rise.   

“We are very excited about this acquisition and the value it will provide our shareholders,” said Endonovo CEO, Alan Collier. “We are adding clinical stage programs and expanding our pipeline of non-invasive electroceuticals into central nervous system disorders, strengthening our intellectual property, and adding market-ready products for the treatment of various soft tissue injuries, post-surgical pain and swelling, as well as chronic wounds,” stated Mr. Collier.

“This acquisition represents a significant milestone for Endonovo and positions the company as the leader in bioelectronic medicine allowing for more favorable financing, uplisting the company’s common stock onto a national stock exchange and providing the company a valuation comparable to other companies in the electrical stimulation/electroceuticals sector,” concluded Mr. Collier.

Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical

Oct 13, 2017

OTC Disclosure & News Service


Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical


Non-Invasive Electroceutical Significantly Increased Cardiac Function and Reduced Ventricular Remodeling in Infarcted Animals

LOS ANGELES, CA--(Marketwired - Oct 13, 2017) -  Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today reported that it has completed a study to evaluate the potential efficacy of its Immunotronics™ platform, a non-invasive electroceutical, in a well-established preclinical model of heart failure (post-MI remodeling). With these positive results, the Company continues to advance the development of its pipeline of non-invasive electroceuticals targeting vascular diseases and inflammatory conditions in vital organs.

The recently completed study investigated the therapeutic efficacy of the Company's Immunotronics™ platform in a widely used mouse model of heart failure (post-MI remodeling). In this model, treatment with the Company's non-invasive electroceutical two or three times per day resulted in significantly increased cardiac function and reduced ventricular remodeling. Treatment with the Company's Immunotronics™ technology two or three times per day resulted in significantly improved Ejection Fraction (EF), Fractional Shortening (FS), Heart Weight-to-Body Weight Ratio (HW/BW), Left Ventricular Diastolic Pressure (LVDP), Left Ventricular End-Systolic Diameter (LVESD), and Interventricular Septal Dimension at Systole (IVSS). The Company will post the data for shareholders on its website shortly.

"Heart failure and vascular diseases are potential clinical targets for our non-invasive electroceuticals. These results demonstrate the incredible potential of electroceutical-based therapies," said Alan Collier, CEO of Endonovo Therapeutics. "We plan to submit our preclinical post-MI remodeling results during 2018 for presentation at a relevant scientific meeting as we continue to advance our class-leading non-invasive electroceuticals toward the clinic."



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#31545  Sticky Note REVERSE STOCK SPLIT 1 FOR 1,000 BUYER BEWARE!!! Biotech_Tradez 10/31/19 11:54:37 AM
#32166   Jury trial scheduled for May. Can't see details though. https://www.courts.mo. Craig305 12/03/20 08:33:36 PM
#32165   Any idea how much is owed? Craig305 12/03/20 06:09:41 PM
#32164   Interesting. I dont see it on Pacer Monitor Craig305 12/03/20 06:08:08 PM
#32163   HOW THE HELL IS BEING SUED BY YOUR Biotech_Tradez 12/03/20 05:14:11 PM
#32162   SO MUCH FOR THAT "NATIONAL ROLLOUT" OF SOFPULSE! Biotech_Tradez 12/03/20 05:11:26 PM
#32161   ENDV BEING SUED BY BRADO, CUNEO, NOLLAU LLC Biotech_Tradez 12/03/20 05:10:49 PM
#32160   This is absolutely insane! Loser piece of shit brojazzy 12/03/20 04:15:58 PM
#32159   FAKE NEWS FRIDAY TOMORROW? Biotech_Tradez 12/03/20 03:37:33 PM
#32158   Mann is cashing in his chips or he Craig305 12/03/20 03:29:21 PM
#32157   I think he has to stay QB or Biotech_Tradez 12/03/20 03:23:24 PM
#32156   Wonder if Collier will give up on the Craig305 12/03/20 03:20:01 PM
#32155   Raised $400k from a $800k face value toxic loan! Biotech_Tradez 12/03/20 03:15:40 PM
#32154   Wow...what a dump! Craig305 12/03/20 03:13:46 PM
#32153   3's are here, and triple zeros only weeks away! Biotech_Tradez 12/03/20 03:03:21 PM
#32152   REVERSE STOCK SPLIT IS COMING!! BUYER BEWARE!! Biotech_Tradez 12/03/20 12:27:22 PM
#32151   Heading to a penny before the end of Biotech_Tradez 12/03/20 12:26:57 PM
#32150   ENDV IS IN A DEATH SPIRAL FINANCING - Biotech_Tradez 12/03/20 12:26:32 PM
#32149   A lot of people looking to dump shares Biotech_Tradez 12/03/20 12:26:05 PM
#32148   INTL is a new market maker on L2 Craig305 12/03/20 11:33:43 AM
#32147   There are quite a few shark MMs on Craig305 12/02/20 03:47:40 PM
#32146   Poor seller trying to unload his shares at Craig305 12/02/20 10:53:07 AM
#32145   Agree. All the insider buying a while back PencilNeckGeek 12/02/20 09:28:53 AM
#32144   BUYER BEWARE!! GOING SUB-PENNY AND THEN REVERSE SPLIT! Biotech_Tradez 12/02/20 08:58:38 AM
#32143   I tried warning people but they all jumped Biotech_Tradez 12/02/20 08:58:06 AM
#32142   Collier made material misrepresentations when he provided grossly Biotech_Tradez 12/02/20 08:56:23 AM
#32141   Sub penny soon Las3r 12/02/20 06:48:23 AM
#32140   CEO here should be behind bars PencilNeckGeek 12/02/20 01:19:58 AM
#32139   .05? Wow, great job shitty management, lock them brojazzy 12/01/20 10:37:37 PM
#32138   It certainly shat itself today. Even had after hours Craig305 12/01/20 05:49:10 PM
#32137   ENDV STOCK = CHEAP TOILET PAPER!! Biotech_Tradez 12/01/20 03:18:18 PM
#32136   They also dropped their appeal of the KVP Biotech_Tradez 12/01/20 11:55:11 AM
#32135   Now postponed to December 16. Craig305 12/01/20 10:56:51 AM
#32134   Why don’t you guys look up a ticker slopak 11/30/20 03:12:22 AM
#32133   Don't expect everyone to have the level of vp_007_99 11/20/20 11:23:35 AM
#32131   CRAIG & BROJAZZY WE NEED TO REPOST THIS Biotech_Tradez 11/19/20 08:58:45 PM
#32130   THIS PIECE OF SHIT IS GOING SUB-PENNY AGAIN! RUN! Biotech_Tradez 11/19/20 08:57:55 PM
#32129   ENDV IS OFFICIALLY IN A DEATH SPIRAL FINANCING! RUN!! Biotech_Tradez 11/19/20 08:57:28 PM
#32128   EQUITY LINE RAISED ONLY $97K IN 9 MONTHS Biotech_Tradez 11/19/20 08:56:47 PM
#32127   INSOLVENT, NO REAL BUSINESS, JUST A STOCK SCAM! Biotech_Tradez 11/19/20 08:54:45 PM
#32126   ZERO MENTION OF BUSINESS, ALL TOXIC NOTE CONVERSIONS! Biotech_Tradez 11/19/20 08:54:02 PM
#32125   3Q ER is out! Craig305 11/19/20 05:50:15 PM
#32124   It appeared to have a solid wall at Craig305 11/18/20 11:40:50 AM
#32123   REVERSE STOCK SPLIT COMING, BUYER BEWARE! Biotech_Tradez 11/17/20 10:21:57 PM
#32122   THIS SCAM IS GOING BACK TO SUB-PENNY! Biotech_Tradez 11/17/20 10:21:25 PM
#32121   IN OTHER WORDS, JUST ANOTHER TUESDAY AT ENDV! Biotech_Tradez 11/17/20 10:20:46 PM
#32120   Yikes, company diluting like there’s no tomorrow! brojazzy 11/17/20 08:42:56 PM
#32119   RUN TO A LIFE BOAT!! GET OFF! Biotech_Tradez 11/17/20 11:44:50 AM
#32118   Hard to run while sinking under water...LOL Craig305 11/17/20 11:41:00 AM
#32117   THIS PIECE OF SHIT IS A SINKING SHIP!! RUN!! Biotech_Tradez 11/17/20 10:52:25 AM
#32116   You seem surprised. All they can do is Biotech_Tradez 11/16/20 11:25:37 PM
Consent Preferences